Neuron23 vs Cradle
Side-by-side comparison of AI visibility scores, market position, and capabilities
$96.5M Series D (2025); NEU-411 LRRK2 inhibitor in Phase 2 NEULARK trial for early Parkinson's disease.
About
Neuron23 is a clinical-stage biotechnology company developing precision medicines for genetically defined neurological and immunological diseases. The company combines advances in human genetics with AI-based drug discovery and biomarker platforms to identify novel molecular targets and advance therapies for conditions with high unmet medical need. Its lead program, NEU-411, is a brain-penetrant, potent, and selective LRRK2 inhibitor targeting early Parkinson's disease.
AI protein design platform combining language models with lab automation; active learning cycles for enzyme, antibody, and therapeutic protein engineering optimization.
About
Cradle is a protein design platform using AI to help biotechnology and pharmaceutical companies engineer better proteins — enzymes, antibodies, and therapeutic proteins — with improved stability, activity, and manufacturability. Founded in 2021 and headquartered in Amsterdam with teams in San Francisco, Cradle raised approximately $24 million and targets biopharmaceutical, agricultural, and industrial biotechnology companies that need to engineer proteins with specific functional properties.
Key Details
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.